Exscientia -Evotec Cancer Therapy Shows Encouraging Action In Healthy Volunteers
Exscientia -Evotec Cancer Therapy Shows Encouraging Action In Healthy Volunteers
ExScience a-Evotec癌症治療在健康志願者中顯示出令人鼓舞的作用
- Exscientia plc (NASDAQ:EXAI) announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2A receptor antagonist.
- The drug candidate is co-invented and developed through a collaboration between Exscientia and Evotec SE (NASDAQ:EVO).
- Topline data confirmed Exscientia's target product profile design, including potency, high receptor selectivity, and expected low brain exposure with no CNS adverse events reported.
- The study showed that observed human PK for EXS-21546 was in line with what had been designed for and predicted in preclinical modeling.
- EXS-21546 showed dose-dependent inhibition of CREB phosphorylation in CD8-positive cells, with the PD profile mirroring plasma exposure.
- Inhibition of A2A receptor signaling was sustained over the BID dosing period, demonstrating lasting target engagement.
- EXS-21546 was well-tolerated, with no CNS adverse events reported in the SAD portion at all doses and the MAD portion at 150mg BID.
- Exscientia expects to initiate a Phase 1b/2 study of EXS-21546 in patients with high adenosine signature solid tumors in the second half of 2022. The Phase 1b/2 study is being designed to evaluate higher doses of EXS-21546.
- Price Action: EXAI shares are down 3.70% at $11.96 during the market session on the last check Tuesday.
- Exscientia plc (NASDAQ:EXAI) announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2A receptor antagonist.
- The drug candidate is co-invented and developed through a collaboration between Exscientia and Evotec SE (NASDAQ:EVO).
- Topline data confirmed Exscientia's target product profile design, including potency, high receptor selectivity, and expected low brain exposure with no CNS adverse events reported.
- The study showed that observed human PK for EXS-21546 was in line with what had been designed for and predicted in preclinical modeling.
- EXS-21546 showed dose-dependent inhibition of CREB phosphorylation in CD8-positive cells, with the PD profile mirroring plasma exposure.
- Inhibition of A2A receptor signaling was sustained over the BID dosing period, demonstrating lasting target engagement.
- EXS-21546 was well-tolerated, with no CNS adverse events reported in the SAD portion at all doses and the MAD portion at 150mg BID.
- Exscientia expects to initiate a Phase 1b/2 study of EXS-21546 in patients with high adenosine signature solid tumors in the second half of 2022. The Phase 1b/2 study is being designed to evaluate higher doses of EXS-21546.
- Price Action: EXAI shares are down 3.70% at $11.96 during the market session on the last check Tuesday.
- ExScience a plc納斯達克(Sequoia Capital：EXAI)宣佈了其高選擇性A2A受體拮抗劑EXS-21546的第一階段健康志願者研究數據。
- 候選藥物是由共同發明和開發的，由ExScience和Evotec SE(納斯達克：evo)。
- TOPLINE數據證實了ExScience a的目標產品配置文件設計，包括效力、高受體選擇性和預期的低腦暴露，沒有中樞神經系統不良事件的報道。
- 研究表明，觀察到的人體EXS-21546的PK與臨牀前建模中設計和預測的一致。
- Exs-21546顯示劑量依賴地抑制CD8陽性細胞中CREB的磷酸化，PD曲線反映了血漿暴露。
- A2a受體信號的抑制在Bid給藥期間持續存在，表明持續的靶向參與。
- Exs-21546耐受性良好，所有劑量的SAD部分和150 mg Bid的MAD部分均未報告中樞不良反應。
- ExScience a希望在2022年下半年啟動EXS-21546在高腺苷簽名實體腫瘤患者中的1b/2期研究。1b/2期研究旨在評估更高劑量的EXS-21546。
- 價格行動：週二尾盤，EXAI股價下跌3.70%，至11.96美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧
點擊這裡與好友分享
暫無評論，快來留言吧！